HER2+ breast cancer: concurrent trastuzumab + anthracyclines found safe

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Concurrent administration of trastuzumab and anthracyclines is no more cardiotoxic than sequential administration to patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer.
  • No difference in DFS or OS was reported between groups.

Why this matters...